US deal to build solid state medical batteries

UK solid state battery developer Ilika has signed a deal with Cirtec Medical to build Stereax mm-scale batteries in the US.

Production at the plant in Massachusetts will boost Cirtec’s ongoing activities in system level miniaturization for the medical device industry. Ilika will focus on advanced technology development and IP licensing to support Cirtec’s manufacturing and commercialization activities.

Cirtec Medical is a vertically integrated outsourcing company providing end-to-end product design, development, and manufacturing of Class III and II medical devices and components. These include neuromodulation, implantable drug delivery, cardiac rhythm management, ventricular assist and interventional devices and delivery systems. The company has manufacturing across the US and in Birkenfeld, Germany.

Ilika plc (LON:IKA) is a pioneer in solid state battery technology enabling solutions for applications in Industrial IoT, MedTech, Electric Vehicles and Consumer Electronics. Stereax enables disruptive product designers looking for a long life (1000s recharges), low leakage (nA) and miniature power source (first product will be 20 mm3) with rectangular form factor similar to ICs.

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
X
LinkedIn
Ilika plc

More articles like this

Ilika plc

Effective power management for rechargeable batteries

As rechargeable batteries become increasingly integrated into our daily lives, ensuring they charge, store, and discharge energy efficiently and safely throughout their operational lifetime is crucial. Typically, this is achieved through a stand-alone Power Management Integrated

Ilika plc

Ilika’s journey from 2015-2019

Ilika plc (LON:IKA) is a pioneer in solid state battery technology enabling solutions for applications in Industrial IoT, MedTech, Electric Vehicles and Consumer Electronics.

Ilika plc

Ilika celebrates 20 years of innovation and growth

Ilika Technologies has reached its 20th anniversary. Originally focused on high-throughput materials discovery, the company was founded by CEO Graeme Purdy to commercialise technology from the University of Southampton’s Department of Chemistry. The early years, led

Ilika plc

Ilika provides comprehensive update on FY24 trading

Ilika’s unaudited trading results for the year ended 30 April 2024 have aligned with management expectations. The Company anticipates reporting revenues of approximately £2.1 million (2023: £0.7 million), with an EBITDA loss excluding share-based payments of